Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Target Price at $12.75

Shares of Pulmonx Co. (NASDAQ:LUNG - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $12.75.

Several equities analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Wednesday, December 11th. Citigroup reaffirmed a "neutral" rating and set a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th.

Pulmonx Stock Performance

Shares of NASDAQ LUNG traded down $0.75 during mid-day trading on Monday, hitting $7.44. 249,341 shares of the company were exchanged, compared to its average volume of 336,387. The stock has a 50 day simple moving average of $6.95 and a 200-day simple moving average of $6.94. Pulmonx has a 1-year low of $5.46 and a 1-year high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a market cap of $296.08 million, a price-to-earnings ratio of -5.17 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million during the quarter, compared to analysts' expectations of $22.29 million. On average, sell-side analysts forecast that Pulmonx will post -1.55 EPS for the current fiscal year.

Remove Ads

Insider Buying and Selling

In other Pulmonx news, Director Glendon E. French III sold 55,453 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares in the company, valued at approximately $8,379,144.72. This trade represents a 5.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven S. Williamson sold 27,689 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total transaction of $197,699.46. Following the completion of the sale, the chief executive officer now directly owns 194,342 shares in the company, valued at $1,387,601.88. This trade represents a 12.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,986 shares of company stock worth $986,673 in the last quarter. Company insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in Pulmonx by 2.6% during the third quarter. State Street Corp now owns 747,028 shares of the company's stock worth $6,193,000 after buying an additional 18,592 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of Pulmonx during the third quarter valued at $1,711,000. Geode Capital Management LLC increased its position in Pulmonx by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 892,786 shares of the company's stock worth $7,403,000 after purchasing an additional 11,151 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new position in Pulmonx in the 3rd quarter valued at about $893,000. Finally, Millrace Asset Group Inc. acquired a new position in Pulmonx in the 3rd quarter valued at about $1,390,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.